Purchase includes Lynnwood, WA Biologics Manufacturing Facility 

BOSTON, MA – February 1, 2018/ PR Newswire/

Boston-based cancer company Partner Therapeutics, Inc. (PTx) announced today that it has acquired the global rights to develop, manufacture, and commercialize Leukine (sargramostim) from Sanofi. Leukine is an immuno-stimulant that promotes the growth and activation of a broad range of white blood cells important in activating the body’s immune response to fight infections. Leukine is used to treat or prevent severe and life-threatening infections and is the ...

Funds to support pipeline development and commercial operations 

BOSTON, MA – February 1, 2018/ PR Newswire/

Partner Therapeutics, Inc. (PTx) announced today the closing of a Series A financing to support the launch and growth of the company. PTx is an oncology company focused on the development and commercialization of approved and late-stage therapies that improve treatment outcomes and reduce the total cost of care.

The financing totaled $60 million and was led by a group of pre-eminent biopharma investors, including Perceptive Advisors, ...

Partner Therapeutics to focus on commercial and late-stage cancer therapies.

BOSTON, Jan. 25, 2018-PRNewswire

Biotech and pharmaceutical executives Robert Mulroy and Dr. Debasish Roychowdhury announced today the launch of Partner Therapeutics, or PTx, an oncology company that is focused on the development and commercialization of approved and late-stage therapies. The Boston-area company is committed to supporting patient care with medicines that improve cancer treatment outcomes and reduce the total cost of care.

Mr. Mulroy and Dr. Roychowdhury are biopharma veterans who combined have ...